¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ 2022 KGOG Symposium & Workshop-1st Methodology Wroshop : 2022-08-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ 2022 KGOG Symposium & Workshop-1st Methodology Wroshop : 2022-08-20
±³À°ÀÏÀÚ : 2022-08-20
±³À°Àå¼Ò : À¯±¤»çȦ, ÃÖ´ö°æ°­ÀÇ½Ç (°í·Á´ëÇб³ÀÇ°ú´ëÇÐ)  
±³À°ÁÖÁ¦ : 2022 KGOG Symposium & Workshop-1st Methodology Wroshop
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸  
´ã´çÀÚ : ±èÀμ÷
¿¬¶ôó : 02-512-5420  
À̸ÞÀÏ : kiskgog@hanmail.net      
±³À°Á¾·ù : »êºÎÀΰú±âŸ
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 45ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-20 À¯±¤»çȦ 09:00~09:15 Overview of enrichment designs  ¼Ò°æ¾Æ(°Ç±¹´ëº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 09:15~09:30 Overview of adaptive designs  ¹é¹ÎÇö(ÇѸ²´ë¼º½Éº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 09:30~09:45 Overview of master protocols  ÀÌ»êÈñ(¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø) 
Åä·Ð 08-20 À¯±¤»çȦ 09:45~10:00 Panel Discussion  ÃÖöÈÆ, ÇÏÁ¤Àº, À̱ÙÈ£(»ï¼º¼­¿ïº´¿ø, ±¹°¡ÀÓ»ó½ÃÇèÁö¿øÀç´Ü, ¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 10:20~10:40 Gynecologic cancer clinical trials in Japan  Keiichi Fujiwara(Saitama Medical University International Medical Center) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 10:40~11:00 DSMB in phase 3 multicenter clinical trial  ·ù±Ù¿ø(±¹¸³¾Ï¼¾ÅÍÀ§¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 11:00~11:20 Road to successful clinical trials in KGOG  ÀÌÁ¤À±(¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 11:20~11:40 Clinical trial of Gynecologic cancer in KROG  ¹Ú¿ø(»ï¼º¼­¿ïº´¿ø) 
Åä·Ð 08-20 À¯±¤»çȦ 11:40~11:55 Panel Discussion  ±è¹Î±Ô,¹èÀ縸,¾ö±Ù¿ë(»ï¼ºÃ¢¿øº´¿ø,ÇѾç´ëº´¿ø,ºÐ´ç¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 11:55~12:15 Pegylated Liposomal Doxorubicin(PLD) in Platinum- Sensitive Recurrent Ovarian Cancer  ÃÖÇöÁø(Á߾Ӵ뱤¸íº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 12:15~12:35 Pegylated Liposomal Doxorubicin(PLD) and bevacizumab combination for recurrent ovarian cancer  Á¤¿ë¿í(°­³²Â÷º´¿ø) 
±³À°½Ã°£ 08-20 ÃÖ´ö°æ°­ÀÇ½Ç 320È£ 11:55~12:15 Why I choose PARPi monotherapy for 1LM  Á¶ÇѺ°(°­³²¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 08-20 ÃÖ´ö°æ°­ÀÇ½Ç 320È£ 12:15~12:35 Clinical decision-making with or without HRD testing  È«¼÷Èñ(¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 13:35~13:55 Study using real world data  ½É½ÂÇõ(°Ç±¹´ëº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 13:55~14:15 Study using public health data  ÃÖÈ¿±Ù(ÇѸ²´ë¼º½Éº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 14:30~14:50 6th Ovarian Cancer Consensus Conference (OCCC)  Àå¼®ÁØ(¾ÆÁִ뺴¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 14:50~15:05 Gynecologic Cancer Inter (GCIG) 2022  Á¶Çö¿õ(°í´ë±¸·Îº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 15:05~15:20 American Society of Clinical Oncology (ASCO) 2022  ³ëÁØÈ£(»ï¼º¼­¿ïº´¿ø) 
Åä·Ð 08-20 À¯±¤»çȦ 15:40~16:00 Panel Discussion  ±è»ó¿î, ³ëÀçÈ«,ÀÌ»óÈÆ(¼¼ºê¶õ½ºº´¿ø, ºÐ´ç¼­¿ï´ëº´¿ø, ¿ï»ê´ëº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 16:00~16:15 Statistics for retrospective studies and meta-analyses  ±èÇöÁ¤(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 16:15~16:30 Multi-Arm Multi-Stage (MAMS) Design in Oncologic Study  ÀÌÁ¤º¹(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 16:30~16:45 Designs for Randomized Phase II Clinical Trials  ³²º´È£(Ç층½º) 
Åä·Ð 08-20 À¯±¤»çȦ 16:45~17:00 Panel Discussion  À̼ºÁ¾,¼Û¿ëÁß,±è±âµ¿(¼­¿ï¼º¸ðº´¿ø,¾ç»êºÎ»ê´ëº´¿ø,ºÐ´ç¼­¿ï´ëº´¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ 2022 KGOG Symposium & Workshop-1st Methodology Wroshop : 2022-08-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) ´ëÇÑ°íÇ÷¾ÐÇÐȸ Á¦78ȸ ¿Â¶óÀÎ °³¿øÀÇ ¹× Àü°øÀÇ ¿¬¼ö°­Á : 2022-08-20
´ÙÀ½±Û ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ ºÎ»êÁöºÎÇÐȸ ÇÏ°èÇмú´ëȸ : 2022-08-20
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20655 ¼­¿ï Á¦ 66ȸ Çѱ¹Ç×°ø¿ìÁÖÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-24 0 37 2024-05-10
20654 ´ëÀü °ø°ø±â°ü ÀçÁ÷ÀÇ»ç Ãá°è Çмú´ëȸ (2ÀÏÂ÷) : 2024-05-24 0 26 2024-05-10
20653 ºÎ»ê ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-24 0 24 2024-05-10
20652 ¼­¿ï Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦ 44 Â÷ KSTH Ãá°èÇмú´ëȸ : 2024-05-24 0 36 2024-05-10
20651 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-°³¿ø°¡¿¡¼­ ÀÇ·ÚµÈ ÀÌ°ú Áúȯ : 2024-05-23 0 25 2024-05-10
20650 °æ±â Çϳ²½ÃÀÇ»çȸ¿¬¼ö°­ÁÂ(¸¸¼º±âħ, ºÒ¸éÁõ) : 2024-05-23 0 16 2024-05-10
20649 ´ëÀü °ø°ø±â°ü ÀçÁ÷ÀÇ»ç Ãá°è Çмú´ëȸ (1ÀÏÂ÷) : 2024-05-23 0 15 2024-05-10
20648 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦1Â÷¿¬¼ö±³À°(ºóÇ÷ ¹× ÃâÇ÷ Áúȯ, ÀÏÂ÷ ÀÇ·á±â°ü¿¡¼­ÀÇ °ü¸®) : 2024-05-23 0 27 2024-05-10
20647 ´ëÀü ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ´ëÀüÃæûÁöȸ - Á¦2Â÷ ¿ù·ÊÁý´ãȸ : 2024-05-23 0 35 2024-05-10
20646 Á¦ÁÖ ´ëÇÑÇǺΰúÇÐȸ Á¦ÁÖÁöºÎȸ 2024³â Á¦1Â÷ Áý´ãȸ : 2024-05-22 0 14 2024-05-10
20645 ´ë±¸ ´ëÇѾȰúÇÐȸ ´ë±¸°æºÏÁöȸ ¿¬¼ö±³À°-¹é³»Àå ¹× Àü¾ÈºÎ ÃֽŠÁö°ß : 2024-05-21 0 13 2024-05-10
20644 ¼­¿ï ¾çõ±¸ÀÇ»çȸ Ãá°è¿¬¼ö±³À°(Á¦2Çü ´ç´¢º´°ú ¸¸¼º ½ÅÀ庴, ÀÎÁöÀå¾Ö, ¸ÞŸ¹ö½º¿Í ÀÇ·á Çõ¸í) : 2024-05-21 0 36 2024-05-10
20643 ÃæºÏ 2024 Á¦Ãµ½ÃÀÇ»çȸ Ãá°è ¿¬¼ö°­Á : 2024-05-21 0 10 2024-05-10
20642 ºÎ»ê Á¦28Â÷ ¾Æ½Ã¾Æ-¿À¼¼¾Æ´Ï¾Æ »êºÎÀΰú¿¬¸Í Çмú´ëȸ (AOFOG 2024) (4ÀÏÂ÷) : 2024-05-20 0 26 2024-05-10
20641 ¼­¿ï ´ëÇÑÀÓ»ó³ëÀÎÀÇÇÐȸ 2024 Ãá°è ³ëÀÎÀÇÇÐ ¿¬¼ö°­Á : 2024-05-19 0 72 2024-05-10
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷